Literature DB >> 8143271

Analysis of oncogene expression in primary human gliomas: evidence for increased expression of the ros oncogene.

D Watkins1, F Dion, M Poisson, J Y Delattre, G A Rouleau.   

Abstract

Expression of a panel of oncogenes and potential oncogenes was studied in normal human brain and in 17 human gliomas, including three low- and 14 high-malignancy-grade tumors. PolyA RNA was isolated from glioma biopsies and used as template for reverse transcriptase-catalyzed synthesis of radioactively labeled cDNA. Labeled cDNA was then hybridized to filters to which probes for various oncogenes had been attached. Increased signal intensity, as compared with that of normal brain, was observed for the ros oncogene in six of 17 gliomas, including gliomas of both low and high malignancy grades. Increased ros expression was verified by Northern blot analysis in one tumor. These results suggest that increased ros expression may play a role in tumorigenesis in a significant proportion of gliomas. Increased expression of other genes, including the erbA2, mel, and ets oncogenes was observed in a smaller proportion of the gliomas tested, suggesting a possible role for these oncogenes in individual tumors but no generalized role in development or progression of human gliomas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8143271     DOI: 10.1016/0165-4608(94)90128-7

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  6 in total

1.  Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma.

Authors:  Alan Charest; Vicky Kheifets; Julie Park; Keara Lane; Kevin McMahon; Cathy L Nutt; David Housman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

Review 2.  Kinase inhibitors in cancer therapy: a look ahead.

Authors:  H H Sedlacek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 3.  The autocrine loop of TGF-alpha/EGFR and brain tumors.

Authors:  P Tang; P A Steck; W K Yung
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

4.  Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma.

Authors:  Chunxiao Liu; Zhengyu Zha; Chenhao Zhou; Yeh Chen; Weiya Xia; Ying-Nai Wang; Heng-Huan Lee; Yirui Yin; Meisi Yan; Chiung-Wen Chang; Li-Chuan Chan; Yufan Qiu; Hui Li; Chia-Wei Li; Jung-Mao Hsu; Jennifer L Hsu; Shao-Chun Wang; Ning Ren; Mien-Chie Hung
Journal:  J Hepatol       Date:  2020-10-05       Impact factor: 25.083

5.  Small-cell lung cancer is characterized by a high incidence of deletions on chromosomes 3p, 4q, 5q, 10q, 13q and 17p.

Authors:  I Petersen; H Langreck; G Wolf; A Schwendel; R Psille; P Vogt; M B Reichel; T Ried; M Dietel
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 6.  ROS1-dependent cancers - biology, diagnostics and therapeutics.

Authors:  Alexander Drilon; Chelsea Jenkins; Sudarshan Iyer; Adam Schoenfeld; Clare Keddy; Monika A Davare
Journal:  Nat Rev Clin Oncol       Date:  2020-08-05       Impact factor: 66.675

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.